Aligos Therapeutics to Present at the Jefferies Global Healthcare Conference
Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will deliver a presentation on Thursday, June 5, 2025, at 2:00 PM ET. Interested parties can access the live webcast through the Presentation & Events section of Aligos' investor relations webpage. A replay will remain available for at least 30 days following the presentation.
Aligos Therapeutics (NASDAQ: ALGS), un'azienda biofarmaceutica in fase clinica specializzata in terapie per malattie epatiche e virali, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il team di gestione dell'azienda terrà una presentazione il giovedì 5 giugno 2025 alle 14:00 ET. Gli interessati potranno seguire la diretta streaming nella sezione Presentazioni ed Eventi della pagina investor relations di Aligos. La registrazione resterà disponibile per almeno 30 giorni dopo la presentazione.
Aligos Therapeutics (NASDAQ: ALGS), una compañía biofarmacéutica en etapa clínica especializada en terapias para enfermedades hepáticas y virales, ha anunciado su participación en la próxima Jefferies Global Healthcare Conference. El equipo directivo de la empresa realizará una presentación el jueves 5 de junio de 2025 a las 2:00 PM ET. Las personas interesadas podrán acceder a la transmisión en vivo a través de la sección Presentaciones y Eventos de la página de relaciones con inversores de Aligos. La repetición estará disponible durante al menos 30 días después de la presentación.
Aligos Therapeutics (NASDAQ: ALGS)는 간 및 바이러스 질환 치료제를 전문으로 하는 임상 단계 생명공학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 회사 경영진은 2025년 6월 5일 목요일 오후 2시(동부시간)에 발표를 진행할 예정입니다. 관심 있는 분들은 Aligos 투자자 관계 웹페이지의 발표 및 이벤트 섹션을 통해 생중계 웹캐스트에 접속할 수 있습니다. 발표 후 최소 30일간 다시보기 서비스도 제공됩니다.
Aligos Therapeutics (NASDAQ: ALGS), une société biopharmaceutique en phase clinique spécialisée dans les thérapies des maladies hépatiques et virales, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. L'équipe de direction de l'entreprise présentera le jeudi 5 juin 2025 à 14h00 ET. Les personnes intéressées peuvent accéder à la diffusion en direct via la section Présentations & Événements de la page relations investisseurs d'Aligos. Une rediffusion sera disponible pendant au moins 30 jours après la présentation.
Aligos Therapeutics (NASDAQ: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Therapien für Leber- und Viruskrankheiten spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jefferies Global Healthcare Conference angekündigt. Das Management-Team des Unternehmens wird am Donnerstag, den 5. Juni 2025, um 14:00 Uhr ET eine Präsentation halten. Interessierte können den Live-Webcast über den Bereich Präsentationen & Veranstaltungen auf der Investor-Relations-Webseite von Aligos verfolgen. Eine Aufzeichnung wird mindestens 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 2:00pm ET.
A live webcast of the presentation will be accessible by visiting the Presentation & Events section on the “Investors” page of Aligos’ website at www.aligos.com. A replay of the webcast will be available following the presentation for at least 30 days.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
Media Contact
Inizio Evoke
Jake Robison
Vice President
Jake.Robison@inzioevoke.com
FAQ
When is Aligos Therapeutics (ALGS) presenting at the Jefferies Healthcare Conference 2025?
How can I watch Aligos Therapeutics' (ALGS) Jefferies conference presentation?
What is Aligos Therapeutics' (ALGS) main business focus?
How long will the replay of ALGS Jefferies conference presentation be available?
